Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DPP-4 inhibitor (siRNA)
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
DPP-4 inhibitor (siRNA) refers to small interfering RNA (siRNA) molecules designed to selectively silence the expression of dipeptidyl peptidase-4 (DPP-4, also known as CD26). DPP-4 is a cell-surface serine exopeptidase that plays a key role in glucose homeostasis by degrading incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). In addition to its metabolic functions, DPP-4 is involved in cell adhesion, immune regulation, and apoptosis. Silencing DPP-4 expression using specific siRNA is widely utilized in preclinical research to investigate the non-glycemic effects of the incretin system, such as its role in cardiovascular protection, endothelial-to-mesenchymal transition (EndMT), and cellular apoptosis.
- Other names
- DPP-4 siRNADPP4 siRNADPP 4 siRNAdipeptidyl peptidase IV siRNAdipeptidyl peptidase-4 siRNA
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on DPP-4 inhibitor (siRNA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DPP-4 inhibitor (siRNA).